Sign in
Taking people in United StatesPhase 4

Early Angiotensin II in the Emergency Department

Key facts

Who runs it
Brett A Faine
Where
Iowa City, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
1 Apr 2025
Expected to end
30 Jan 2027
Type of study
Interventional
Treatments tested
  • Angiotensin II Infusion
Record updated
2 September 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥18; and
  • Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
  • Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
  • Can provide written informed consent (or legally authorized representative)

Who cannot take part

  • Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells)
  • Acute coronary syndrome
  • Patients with a history of mesenteric ischemia
  • Patients with a history of having an aortic dissection or abdominal aortic aneurysm
  • Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis
  • Cardiogenic shock
  • Patients with an expected lifespan of <12 hours
  • Active administration of two vasoactive agents before enrollment; and

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial is currently available in United States.

  • University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Brett FaineTaking people

About the trial

What the trial wants to find out

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

The group in the trial

  • Angiotensin II InfusionTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study
Criteria questions
Built from NCT06693726, who can take part
Record updated
2 September 2026